A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)

PI Joel Trugman, MD

Primary endpoint

Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period

Population

Episodic Migraine; n=910

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The ADVANCE (atogepant) trial's stated primary conclusion — Atogepant, an oral CGRP receptor antagonist, reduces monthly migraine days in episodic migraine preventive therapy. — replicates in independent cohorts.

neurology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of ADVANCE (atogepant) are confirming the original effect size in real-world data.

neurology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, oral CGRP antagonists will be first-line preventive therapy for episodic migraine, surpassing beta-blockers in new prescriptions.

neurology

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT01035255

0.2295

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT04816591

0.2300

· 3 claims

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

NCT02484547

0.2345

· 3 claims

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

NCT01804355

0.2403

· 3 claims

A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke

NCT00707304

0.2437

· 3 claims

FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

NCT01778335

0.2489

· 3 claims

Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke